Sangamo Biosciences Inc (SGMO)

[surf1944]

1:08AM Sangamo BioSci presents groundbreaking clinical data from ZFN therapeutic for HIV/AIDS (SGMO) 6.00 : Co presents data from all dosing cohorts of Sangamo's Phase 1 dose escalation study in subjects on highly active antiretroviral therapy who entered the study with CD4+ T-cells counts of <500 cells/mm3 after several years of therapy. Data from these presentations demonstrate: 1)A statistically significant relationship between suppression of HIV viral load and calculated levels of circulating CD4+ T-cells that have undergone biallelic modification of the CCR5 gene in SB-728-T-treated individuals who underwent a TI. CCR5 is the major co-receptor used by HIV to infect cells of the immune system. 2)The VL of one SB-728-T treated-subject decreased to undetectable levels during a TI. This subject was found to be heterozygous for the CCR5 delta-32 gene mutation, i.e. half that subject's CCR5 genes were naturally disrupted. 3)Confirmation and extension of previous observations of unprecedented improvements in overall CD4+ T-cell counts and CD4+ : CD8+ T-cell ratios, as well as engraftment, expansion, trafficking and persistence of the ZFN modified cells. 4) SB-728-T treatment continues to be safe and well tolerated.